An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer
| Autor: | Hiroya Yamashita, Makoto Fukuda, Kazuharu Nagao, Kenichirou Baba, Haruhiko Miyayama, Yukio Matsuoka, Masakazu Matsuda, Reiki Nishimura |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Oncology medicine.medical_specialty medicine.medical_treatment Advanced breast Breast Neoplasms Pathological response Mastectomy Segmental Disease-Free Survival Drug Administration Schedule Breast cancer Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Neoplasm Invasiveness Pharmacology (medical) Radiology Nuclear Medicine and imaging Primary chemotherapy Cyclophosphamide Aged Epirubicin Neoplasm Staging Probability Response rate (survey) Chemotherapy Dose-Response Relationship Drug business.industry Biopsy Needle Cytarabine Cancer General Medicine Middle Aged Prognosis medicine.disease Survival Rate Logistic Models Treatment Outcome Female Fluorouracil business Follow-Up Studies |
| Zdroj: | Breast Cancer. 9:145-152 |
| ISSN: | 1880-4233 1340-6868 |
| DOI: | 10.1007/bf02967579 |
| Popis: | The usefulness of primary chemotherapy has been widely recognized and applied to routine clinical practice to improve prognosis by downstaging. Nevertheless, none of many trials has been able to show a positive effect of primary chemotherapy in terms of prognosis, and predictive factors of outcome have not been defined and are still under investigation. Primary chemotherapy was given to 50 patients with advanced breast cancer. Predictive factors involved in clinical or pathological response to primary chemotherapy (3 cycles of CE(F) therapy) were investigated. The response rate in all patients was 56.0% (CR: 3 patients PR: 25 patients) and 64.1% in patients without distant metastases. MIB-1 was related to the clinical response and EIC (extensive intraductal component) was related to the pathological response; the response was high in patients with EIC negative tumors. Responders had tumors with higher proliferative activity, which decreased significantly after chemotherapy. Patients with a decrease of more than 30% in proliferative activity after chemotherapy had significantly higher disease-free survival rates. The proliferative activity and EIC status were useful predictors of clinical or pathological response to primary chemotherapy. A decrease in proliferative activity by chemotherapy significantly correlated with clinical response and reflected a favorable prognosis. The number of patients benefiting from primary chemotherapy might steadily increase by detecting these predictive factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink